Interaction between gut microbiome and cardiovascular disease

Life Sciences

Volumn 214, Issue , 2018, Pages 153-157

  Peng, Jieting ^a   Xiao, Xun ^a   Hu, Min ^a   Zhang, Xiangyu ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cardiovascular disease; Gut microbiome; Short chain fatty acids; Trimethylamine; Trimethylamine N oxide

Indexed keywords

ENZYME INHIBITOR; MINOCYCLINE; PROBIOTIC AGENT; SACCHAROMYCES BOULARDII CONCENTRATE; SHORT CHAIN FATTY ACID; TRIMETHYLAMINE OXIDE; METHYLAMINE; TRIMETHYLOXAMINE; VOLATILE FATTY ACID;

ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE; DRUG TARGETING; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; INTESTINE FLORA; ISCHEMIC HEART DISEASE; MICROBIAL METABOLISM; NONHUMAN; PATHOGENESIS; REVIEW; FECAL MICROBIOTA TRANSPLANTATION; METABOLISM; MICROBIOLOGY;

CARDIOVASCULAR DISEASES; FATTY ACIDS, VOLATILE; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MICROBIOME; HUMANS; METHYLAMINES; PROBIOTICS;

EID: 85055975472     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2018.10.063     Document Type: Review

References (72)

1. Writing Group M, Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 133 (2016), e38–360.
2. Aron-Wisnewsky, J., Clement, K., The gut microbiome, diet, and links to cardiometabolic and chronic disorders. Nat. Rev. Nephrol. 12 (2016), 169–181.
3. Kholy, K.E., Genco, R.J., Van Dyke, T.E., Oral infections and cardiovascular disease. Trends Endocrinol Metab 26 (2015), 315–321.
4. Lourenvarsigmao, T.G.B., Spencer, S.J., Alm, E.J., Colombo, A.P.V., Defining the gut microbiota in individuals with periodontal diseases: an exploratory study. J. Oral Microbiol., 10, 2018, 1487741.
5. Eckburg, Paul B., Bik, Elisabeth M., Bernstein, Charles N., Diversity of the human intestinal microbial flora. Science 308:5728 (2005), 1635–1638.
6. Marques, F.Z., Nelson, E., Chu, P.Y., Horlock, D., Fiedler, A., Ziemann, M., et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Circulation 135 (2017), 964–977.
7. Gan, X.T., Ettinger, G., Huang, C.X., Burton, J.P., Haist, J.V., Rajapurohitam, V., et al. Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circ. Heart Fail. 7 (2014), 491–499.
8. Tang, W.H.W., Wang, Z., Levison, B.S., Koeth, R.A., Britt, E.B., Fu, X., et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 368 (2013), 1575–1584.
9. Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K.S., Manichanh, C., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464 (2010), 59–65.
10. Wang, Z., Klipfell, E., Bennett, B.J., Koeth, R., Levison, B.S., Dugar, B., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472 (2011), 57–63.
11. Craciun, S., Balskus, E.P., Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 21307–21312.
12. Wang, Z., Tang, W.H.W., Buffa, J.A., Fu, X., Britt, E.B., Koeth, R.A., et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine‑N‑oxide. Eur. Heart J. 35 (2014), 904–910.
13. Craciun, S., Marks, J.A., Balskus, E.P., Characterization of choline trimethylamine‑lyase expands the chemistry of glycyl radical enzymes. ACS Chem. Biol. 9 (2014), 1408–1413.
14. Tang, W.H., Hazen, S.L., The contributory role of gut microbiota in cardiovascular disease. J. Clin. Invest. 124 (2014), 4204–4211.
15. Bennett, B.J., de Aguiar Vallim, T.Q., Wang, Z., Shih, D.M., Meng, Y., Gregory, J., et al. Trimethylamine‑N‑oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 17 (2013), 49–60.
16. Fennema, D., Phillips, I.R., Shephard, E.A., Trimethylamine and trimethylamine N-oxide, a flavin-containing monooxygenase 3 (FMO3)-mediated host-microbiome metabolic axis implicated in health and disease. Drug Metab. Dispos. 44 (2016), 1839–1850.
17. Gaci, N., Borrel, G., Tottey, W., O'Toole, P.W., Brugere, J.F., Archaea and the human gut: new beginning of an old story. World J. Gastroenterol. 20 (2014), 16062–16078.
18. Messenger, Jeffrey, Clark, Shane, A review of trimethylaminuria (fish odor syndrome). J. Clin. Aesth. Dermatol. 6:11 (2013), 45–48.
19. Shih, D.M., Wang, Z., Lee, R., Meng, Y., Che, N., Charugundla, S., et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J. Lipid Res. 56 (2015), 22–37.
20. Warrier, Manya, Shih, Diana M., et al. The TMAO Generating Enzyme Flavin Monooxygenase 3 is a Central Regulator of Cholesterol Balance. Author manuscript. July 2016, 14.
21. Miao, J., Ling, A.V., Manthena, P.V., Gearing, M.E., Graham, M.J., Crooke, R.M., et al. Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nat. Commun., 6, 2015, 6498.
22. Scheppach, W., et al. Effects of short chain fatty acids on gut morphology and function. Gut(supplement 1), 1994, S35–S38.
23. Li, L., Ma, L., Fu, P., Gut microbiota-derived short-chain fatty acids and kidney diseases. Drug Des. Devel. Ther. 11 (2017), 3531–3542.
24. Koh, A., De Vadder, F., Kovatcheva-Datchary, P., Backhed, F., From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165 (2016), 1332–1345.
25. Wong, J., Piceno, Y.M., DeSantis, T.Z., Pahl, M., Andersen, G.L., Vaziri, N.D., Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am. J. Nephrol. 39 (2014), 230–237.
26. Dewulf, Evelyne M., Cani, Patrice D., Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 62 (2013), 1112–1121.
27. Randrianarisoa, E., Lehn-Stefan, A., Wang, X., Hoene, M., Peter, A., Heinzmann, S.S., et al. Relationship of serum trimethylamine N‑oxide (TMAO) levels with early atherosclerosis in humans. Sci. Rep., 6, 2016.
28. Senthong, V., Wang, Z., Li, X.S., Fan, Y., Wu, Y., Tang, W.H., et al. Intestinal Microbiota-generated metabolite trimethylamine‑N‑oxide and 5-year mortality risk in stable coronary artery disease: the contributory role of intestinal microbiota in a COURAGE-like patient cohort. J. Am. Heart Assoc., 5, 2016.
29. Stubbs, J.R., House, J.A., Ocque, A.J., Zhang, S., Johnson, C., Kimber, C., et al. Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden. J Am Soc Nephrol 27 (2016), 305–313.
30. Benjamin, E.J., Blaha, M.J., Chiuve, S.E., Cushman, M., Das, S.R., Deo, R., et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 135 (2017), e146–e603.
31. Wu, Z.X., Li, S.F., Chen, H., Song, J.X., Gao, Y.F., Zhang, F., et al. The changes of gut microbiota after acute myocardial infarction in rats. PLoS One, 12, 2017, e0180717.
32. Haghikia, A., Li, X.S., Liman, T.G., Bledau, N., Schmidt, D., Zimmermann, F., et al. Gut microbiota-dependent trimethylamine N-oxide predicts risk of cardiovascular events in patients with stroke and is related to proinflammatory monocytes. Arterioscler. Thromb. Vasc. Biol. 38 (2018), 2225–2235.
33. Suzuki, T., Heaney, L.M., Jones, D.J., Ng, L.L., Trimethylamine N-oxide and risk stratification after acute myocardial infarction. Clin. Chem. 63 (2017), 420–428.
34. Lam, V., Su, J., Koprowski, S., Hsu, A., Tweddell, J.S., Rafiee, P., et al. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J. 26 (2012), 1727–1735.
35. Lam, V., Su, J., Hsu, A., Gross, G.J., Salzman, N.H., Baker, J.E., Intestinal microbial metabolites are linked to severity of myocardial infarction in rats. PLoS One, 11, 2016, e0160840.
36. Koeth, R.A., Wang, Z., Levison, B.S., Buffa, J.A., Org, E., Sheehy, B.T., et al. Intestinal microbiota metabolism of L‑carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19 (2013), 576–585.
37. Robles-Vera, I., Toral, M., Romero, M., Jimenez, R., Sanchez, M., Perez-Vizcaino, F., et al. Antihypertensive effects of probiotics. Curr. Hypertens. Rep., 19, 2017, 26.
38. Ma, G., Pan, B., Chen, Y., Guo, C., Zhao, M., Zheng, L., et al. Trimethylamine N-oxide in atherogenesis: impairing endothelial self-repair capacity and enhancing monocyte adhesion. Biosci. Rep., 37(2), 2017, 10.1042/BSR20160244.
39. Zhu, W., Gregory, J.C., Org, E., Buffa, J.A., Gupta, N., Wang, Z., et al. Gut Microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165 (2016), 111–124.
40. Karbach, S.H., Schonfelder, T., Brandao, I., Wilms, E., Hormann, N., Jackel, S., et al. Gut microbiota promote angiotensin II-induced arterial hypertension and vascular dysfunction. J. Am. Heart Assoc., 5, 2016, e003698.
41. Barnes, D.G., Vidiassov, M., Ruthensteiner, B., Fluke, C.J., Quayle, M.R., McHenry, C.R., Embedding and publishing interactive, 3‑dimensional, scientific figures in Portable Document Format (PDF) files. PLoS One, 8, 2013, e69446.
42. Yan, Q., Gu, Y., Li, X., Yang, W., Jia, L., Chen, C., et al. Alterations of the gut microbiome in hypertension. Front. Cell. Infect. Microbiol., 7, 2017, 381.
43. Ufnal, M., Jazwiec, R., Dadlez, M., Drapala, A., Sikora, M., Skrzypecki, J., Trimethylamine‑N‑oxide: a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin II in rats. Can. J. Cardiol. 30 (2014), 1700–1705.
44. Yang, T., Santisteban, M.M., Rodriguez, V., Li, E., Ahmari, N., Carvajal, J.M., et al. Gut dysbiosis is linked to hypertension. Hypertension 65 (2015), 1331–1340.
45. Li, J., Zhao, F., Wang, Y., Chen, J., Tao, J., Tian, G., et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome, 5, 2017, 14.
46. Gomez-Arango, L.F., Barrett, H.L., McIntyre, H.D., Callaway, L.K., Morrison, M., Dekker Nitert, M., et al. Increased systolic and diastolic blood pressure is associated with altered gut microbiota composition and butyrate production in early pregnancy. Hypertension 68 (2016), 974–981.
47. Pluznick, Jennifer L., A novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes 5:2 (April 2014), 202–207.
48. Santisteban, M.M., Qi, Y., Zubcevic, J., Kim, S., Yang, T., Shenoy, V., et al. Hypertension-linked pathophysiological alterations in the gut. Circ. Res. 120 (2017), 312–323.
49. Kociol, R.D., Pang, P.S., Gheorghiade, M., Fonarow, G.C., O'Connor, C.M., Felker, G.M., Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J. Am. Coll. Cardiol. 56 (2010), 1071–1078.
50. Suzuki, T., Heaney, L.M., Bhandari, S.S., Jones, D.J., Ng, L.L., Trimethylamine N-oxide and prognosis in acute heart failure. Heart 102 (2016), 841–848.
51. Nagatomo, Y., Tang, W.H., Intersections between microbiome and heart failure: revisiting the gut hypothesis. J. Card. Fail. 21 (2015), 973–980.
52. Organ, C.L., Otsuka, H., Bhushan, S., Wang, Z., Bradley, J., Trivedi, R., et al. Choline diet and its gut microbe-derived metabolite, trimethylamine N-oxide, exacerbate pressure overload-induced heart failure. Circ. Heart Fail., 9, 2016, e002314.
53. Tang, W.H., Wang, Z., Fan, Y., Levison, B., Hazen, J.E., Donahue, L.M., et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine‑N‑oxide in patients with heart failure: refining the gut hypothesis. J. Am. Coll. Cardiol. 64 (2014), 1908–1914.
54. Wang, Z., Roberts, A.B., Buffa, J.A., Levison, B.S., Zhu, W., Org, E., et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163 (2015), 1585–1595.
55. Chan, Y.K., El-Nezami, H., Chen, Y., Kinnunen, K., Kirjavainen, P.V., Probiotic mixture VSL#3 reduce high fat diet induced vascular inflammation and atherosclerosis in ApoE(-/-) mice. AMB Express, 6, 2016, 61.
56. Khalesi, S., Sun, J., Buys, N., Jayasinghe, R., Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension 64 (2014), 897–903.
57. Yu, L., Meng, G., Huang, B., Zhou, X., Stavrakis, S., Wang, M., et al. A potential relationship between gut microbes and atrial fibrillation: trimethylamine N-oxide, a gut microbe-derived metabolite, facilitates the progression of atrial fibrillation. Int. J. Cardiol. 255 (2018), 92–98.
58. Chen, K., Zheng, X., Feng, M., Li, D., Zhang, H., Gut microbiota-dependent metabolite trimethylamine N-oxide contributes to cardiac dysfunction in western diet-induced obese mice. Front. Physiol., 8, 2017, 139.
59. Svingen, G.F.T., Zuo, H., Ueland, P.M., Seifert, R., Loland, K.H., Pedersen, E.R., et al. Increased plasma trimethylamine-N-oxide is associated with incident atrial fibrillation. Int. J. Cardiol. 267 (2018), 100–106.
60. Zhang, H., Meng, J., Yu, H., Trimethylamine N-oxide supplementation abolishes the cardioprotective effects of voluntary exercise in mice fed a western diet. Front. Physiol., 8, 2017, 944.
61. Romano, K.A., Vivas, E.I., Amador-Noguez, D., Rey, F.E., Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. MBio, 6, 2015, e02481.
62. Azuma, Mitsuhiro, Takahashi, Kyoko, Taurine attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac myocytes. Eur. J. Pharmacol. 403 (2000), 181–188.
63. Costanza, A.C., Moscavitch, S.D., Faria Neto, H.C., Mesquita, E.T., Probiotic therapy with Saccharomyces boulardii for heart failure patients: a randomized, double-blind, placebo-controlled pilot trial. Int. J. Cardiol. 179 (2015), 348–350.
64. Broekaert, W.F., Courtin, C.M., Verbeke, K., Van de Wiele, T., Verstraete, W., Delcour, J.A., Prebiotic and other health-related effects of cereal-derived arabinoxylans, arabinoxylan-oligosaccharides, and xylooligosaccharides. Crit. Rev. Food Sci. Nutr. 51 (2011), 178–194.
65. Tremaroli, V., Backhed, F., Functional interactions between the gut microbiota and host metabolism. Nature 489 (2012), 242–249.
66. Bidulescu, A., Chambless, L.E., Siega-Riz, A.M., Zeisel, S.H., Heiss, G., Usual choline and betaine dietary intake and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. BMC Cardiovasc. Disord., 7, 2007, 20.
67. Gupta, Shaan, Allen-Vercoe, Emma, Fecal microbiota transplantation: in perspective. Ther. Adv. Gastroenterol. 9:2 (2016), 229–239.
68. Kelly, C.R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 149 (2015), 223–237.
69. Adnan, S., Nelson, J.W., Ajami, N.J., Venna, V.R., Petrosino, J.F., Bryan, R.M. Jr., et al. Alterations in the gut microbiota can elicit hypertension in rats. Physiol. Genomics 49 (2017), 96–104.
70. Eme, L., Doolittle, W.F., Archaea. Curr. Biol. 25 (2015), R851–R855.
71. Chistiakov, D.A., Melnichenko, A.A., Myasoedova, V.A., Grechko, A.V., Orekhov, A.N., Mechanisms of foam cell formation in atherosclerosis. J. Mol. Med., 2017, 10.1007/s00109-017-1575-8.
72. Zhao, Z.Z., Wang, Z., Li, G.H., Wang, R., Tan, J.M., Cao, X., et al. Hydrogen sulfide inhibits macrophage-derived foam cell formation. Exp. Biol. Med. 236 (2011), 169–176.